BioTime Stock Jumps 22 Percent in Two Days in Wake of Geron Deal

The stock price of Biotime, Inc., of
Alameda, Ca., shot up more than 12 percent today following the
announcement of a complex deal that will give it the stem cell assets
of Geron Corp., the first firm to launch a clinical trial for an hESC
therapy.

Geron stock price Jan. 2-8
Google chart
BioTime stock closed at $3.88, up
43 cents or 12.46 percent. That followed a 9.6 percent gain
yesterday. Geron's stock closed at $1.63, up three cents or 1.9
percent.
News coverage of the deal was light
with our tracking showing only one story so far today on The Scientist magazine web site.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/mQRu0qUrqwM/biotime-stock-jumps-22-percent-in-two.html

Related Posts

Comments are closed.